CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Mr. Arthur Kuan 2017 'den beri şirketle birlikte olan CG Oncology Inc 'in Chairman of the Board 'ıdır.
CGON hissesinin fiyat performansı nasıl?
CGON 'in mevcut fiyatı $69.51 'dir, son işlem günde 0.03% azalmış etti.
CG Oncology Inc için ana iş temaları veya sektörler nelerdir?
CG Oncology Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
CG Oncology Inc 'in piyasa değerlemesi nedir?
CG Oncology Inc 'in mevcut piyasa değerlemesi $5.8B 'dir
CG Oncology Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 16 analist CG Oncology Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 13 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
